CordenPharma has announced a peptide manufacturing capacity expansion at its GMP API facility in Boulder, Colorado (US).
Already known for its unique large-scale peptide offering with a 10,000 L SPPS (Solid-Phase Peptide Synthesis) vessel, and a 100 cm high-pressure reverse phase purification column, CordenPharma Colorado is recognised as the largest worldwide peptide API producer leading the global peptide market.
In order to accommodate a large spike in the demand for peptide APIs, and to continue an overall growth strategy, CordenPharma Colorado recently completed an expansion of their solid-phase peptide manufacturing capacity.
Dr Matthieu Giraud, Director of Global Peptides, Lipids & Carbohydrates Platform, explained: "With the addition of this extra-large 3,000 L SPPS vessel, our assembly-time, capacity and flexibility has been significantly increased, reinforcing CordenPharma Colorado as the current large-scale peptide manufacturing capacity leader. This new asset gives us the ability to manufacture a complex long peptide with a 400 kg output per single batch. Our team in Colorado aims to utilise this new capacity to conduct validation campaigns designed to support customer projects with a global impact."
With approximately 300 employees, CordenPharma Colorado has grown a strong focus in the development & manufacturing of APIs from laboratory-scale to commercialisation at ton-scale, due to their unique large-scale SPPS capabilities.
The purification of the final peptide is performed at any scale in columns ranging from 5 cm to 100 cm. To avoid the tedious and poor productivity of the final isolation step by lyophilisation, their development team gained expertise in peptide precipitation that successfully transferred to production in commercial products. The site has a long track record in large-scale manufacturing, where all potencies, including picogram levels, can be reached.
